Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.00

Xeris Biopharma (NASDAQ:XERS) had its target price raised by investment analysts at Leerink Partners from $5.00 to $6.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Leerink Partners’ price objective would indicate a potential upside of 42.42% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research report on Friday. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday. Finally, Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.92.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS traded down $0.03 during midday trading on Friday, hitting $4.21. The company’s stock had a trading volume of 588,158 shares, compared to its average volume of 1,907,529. The business’s fifty day simple moving average is $3.57 and its two-hundred day simple moving average is $3.26. The firm has a market capitalization of $628.08 million, a price-to-earnings ratio of -9.30 and a beta of 2.32. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.50.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of XERS. China Universal Asset Management Co. Ltd. grew its stake in Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock worth $107,000 after acquiring an additional 2,954 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after purchasing an additional 3,447 shares in the last quarter. GPS Wealth Strategies Group LLC raised its stake in shares of Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after acquiring an additional 3,900 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after buying an additional 5,500 shares during the period. Finally, Prudential Financial Inc. lifted its position in Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after acquiring an additional 7,000 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.